Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Lekha Mikkilineni, Mark P. Hamilton, Alexandria Jensen, Kenneth JC Lim, Gliceida M. Galarza-Fortuna, Anupama D. Kumar, Christopher J. Ferreri, Andrew J. Portuguese, Hitomi Hosoya, Sharlene Dong, Nadine H. Abdallah, Jinming Song, Rebecca Gonzalez, Anna Shestakova, Navreet Chowla, Zongming Eric Chen, Amandeep Godara, Ghulam Rehman Mohyuddin, Max N. Brondfield, Dana Balitzer, Christopher J. Bowman, Omar Castaneda Puglianini, Michael G. Kattah, Frederick L. Locke, Louis S. Williams, Alaa Ali, Binod
Nature Medicine · Springer Nature · 2026-11-19 · DOI: 10.1038/s41591-026-04783-y

Аннотация

Nature Medicine, Published online: 19 November 2026; doi:10.1038/s41591-026-04783-y In a large multicenter case series, only 32% of patients who developed immune effector cell-associated enterocolitis following treatment with BCMA-directed CAR T cells had achieved disease resolution at last follow-up, with some deaths directly attributable to complications of this disorder.

Читать у издателя →

Похожие статьи